Portfolio Holdings Detail for ISIN IE00BYVJRR92
Stock Name / Fund iShares MSCI USA SRI UCITS ETF USD (Acc)
Issuer Blackrock
Entity holding fund iShares IV Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF Ticker SUUS(GBX) LSE
ETF Ticker QDVR(EUR) F
ETF Ticker QDVR.DE(EUR) CXE
ETF Ticker SUAS.LS(USD) CXE
ETF Ticker SUASz(USD) CXE
ETF Ticker SUAU.AS(EUR) CXE
ETF Ticker SUAS(EUR) ETF Plus
ETF Ticker SUAU(EUR) Euronext Amsterdam
ETF Ticker SUUS.L(GBP) LSE

Holdings detail for ALNY

Stock Name	Alnylam Pharmaceuticals Inc
Ticker	ALNY(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US02043Q1076
LEI	529900S3ZI14OWRJII50

Show aggregate ALNY holdings

News associated with ALNY

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by Royal Bank Of Canada from $435.00 to $500.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. ALNY has been the topic of several other reports. The Goldman Sachs Group boosted their price […] - 2025-09-22 02:32:43
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $520.00 Price Target at Bank of America: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective raised by Bank of America from $453.00 to $520.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also weighed in on ALNY. Oppenheimer upgraded shares […] - 2025-09-18 04:26:54
The Goldman Sachs Group Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by The Goldman Sachs Group from $504.00 to $566.00 in a report published on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on the stock. Chardan Capital lifted […] - 2025-09-17 03:14:44
Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $421.28: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-seven analysts that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and twenty-three have issued a buy recommendation on the company. The average 1 year target price […] - 2025-09-15 02:47:58
Alnylam Announces Pricing Of Upsized Offering Of $575 Mln Convertible Senior Notes Due 2028: (RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced the pricing of its private offering of $575 million aggregate principal amount of 0.00% convertible senior notes due 2028. The size of the offering was increased from the previously announced offering of $500 million aggre - 2025-09-10 00:33:28
Alnylam Pharma Commences Private Offering Of $500 Mln Of Convertible Senior Notes Due 2028: (RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028. In connection with this offering, Alnylam expects to grant the initial purchasers of the notes an op - 2025-09-09 00:30:30
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win: Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study. - 2025-09-01 11:50:00
Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11
Dennis A. Ausiello Sells 31,448 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Dennis A. Ausiello sold 31,448 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the sale, the director directly owned 911 shares in […] - 2025-08-18 05:14:55
LPL Financial LLC Buys 2,107 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): LPL Financial LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 11.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,679 shares of the biopharmaceutical company’s stock after acquiring an additional 2,107 shares during the period. LPL Financial LLC’s holdings […] - 2025-08-13 05:04:56
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Cetera Investment Advisers Has $2.17 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Cetera Investment Advisers raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 68.1% during the first quarter, Holdings Channel reports. The firm owned 8,017 shares of the biopharmaceutical company’s stock after purchasing an additional 3,247 shares during the period. Cetera Investment Advisers’ holdings in Alnylam Pharmaceuticals were worth $2,165,000 at the end […] - 2025-08-08 04:44:59
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at Oppenheimer: Oppenheimer upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a market perform rating to an outperform rating in a research report sent to investors on Monday, Marketbeat.com reports. The brokerage currently has $490.00 target price on the biopharmaceutical company’s stock. ALNY has been the subject of several other reports. Barclays lifted their price […] - 2025-08-07 02:54:47
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by Wolfe Research to Peer Perform Rating: Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by equities research analysts at Wolfe Research from an “underperform” rating to a “peer perform” rating in a research report issued on Monday, Marketbeat reports. A number of other brokerages have also recently issued reports on ALNY. Canaccord Genuity Group lifted their price target on shares […] - 2025-08-06 03:02:54
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $400.00 at Chardan Capital: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Chardan Capital from $325.00 to $400.00 in a research report report published on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also issued reports on ALNY. Needham & Company LLC raised their […] - 2025-08-04 02:48:47
Needham & Company LLC Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $478.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target hoisted by Needham & Company LLC from $377.00 to $478.00 in a research report report published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts also recently commented on the […] - 2025-08-03 05:28:56
Noteworthy ETF Outflows: XBI, MRNA, ALNY, EXEL: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $225.3 million dollar outflow -- that's a 4.6% decrease week over week - 2025-07-30 11:49:03
Y Intercept Hong Kong Ltd Has $1 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Y Intercept Hong Kong Ltd lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 17.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,720 shares of the biopharmaceutical company’s stock after selling 796 shares during the period. […] - 2025-07-25 06:12:53
Victory Capital Management Inc. Cuts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Victory Capital Management Inc. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,649 shares of the biopharmaceutical company’s stock after selling 2,148 shares during the period. Victory Capital […] - 2025-07-25 05:14:50
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the twenty-six research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twenty-two have assigned a buy recommendation to the […] - 2025-07-24 06:26:55
Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Truist Financial: Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report sent to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $385.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts also recently issued reports on ALNY. Jefferies Financial […] - 2025-07-22 03:14:59
Nisa Investment Advisors LLC Cuts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Nisa Investment Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 38.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,155 shares of the biopharmaceutical company’s stock after selling 5,162 shares during […] - 2025-07-14 05:54:56
Crossmark Global Holdings Inc. Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Crossmark Global Holdings Inc. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,018 shares of the biopharmaceutical company’s stock, valued at approximately $275,000. Other hedge funds have also modified their holdings of the […] - 2025-07-14 05:14:48
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Vontobel Holding Ltd.: Vontobel Holding Ltd. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,691 shares of the biopharmaceutical company’s stock after selling 113 shares during the […] - 2025-07-08 04:40:51
Mirae Asset Global Investments Co. Ltd. Sells 2,596 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Mirae Asset Global Investments Co. Ltd. reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 28.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,534 shares of the biopharmaceutical company’s stock after selling 2,596 shares during the […] - 2025-07-04 04:52:27
Wells Fargo & Company Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $333.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price target lifted by research analysts at Wells Fargo & Company from $287.00 to $333.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside […] - 2025-07-02 03:05:01
Diversified Trust Co Sells 999 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Diversified Trust Co cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 40.3% in the first quarter, Holdings Channel reports. The institutional investor owned 1,482 shares of the biopharmaceutical company’s stock after selling 999 shares during the period. Diversified Trust Co’s holdings in Alnylam Pharmaceuticals were worth $400,000 as of […] - 2025-07-01 07:10:56
Sequoia Financial Advisors LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Sequoia Financial Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 3.0% in the first quarter, HoldingsChannel reports. The fund owned 3,395 shares of the biopharmaceutical company’s stock after acquiring an additional 99 shares during the period. Sequoia Financial Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $917,000 […] - 2025-07-01 05:22:50
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High Following Analyst Upgrade: Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) hit a new 52-week high on Monday after Wells Fargo & Company raised their price target on the stock from $287.00 to $333.00. Wells Fargo & Company currently has an equal weight rating on the stock. Alnylam Pharmaceuticals traded as high as $327.05 and last […] - 2025-07-01 02:27:01
Kentucky Retirement Systems Buys New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Kentucky Retirement Systems bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,794 shares of the biopharmaceutical company’s stock, valued at approximately $2,375,000. Several other institutional investors and […] - 2025-06-24 06:20:52

iShares MSCI USA SRI UCITS ETF USD (Acc) ALNY holdings

Date	Number of ALNY Shares Held	Base Market Value of ALNY Shares	Local Market Value of ALNY Shares	Change in ALNY Shares Held	Change in ALNY Base Value	Current Price per ALNY Share Held	Previous Price per ALNY Share Held
2025-12-24 (Wednesday)	35,537	USD 14,239,321	USD 14,239,321	0	USD 70,719	USD 400.69	USD 398.7
2025-12-23 (Tuesday)	35,537	USD 14,168,602	USD 14,168,602	135	USD -265,855	USD 398.7	USD 407.73
2025-12-22 (Monday)	35,402	USD 14,434,457	USD 14,434,457	-162	USD 200,677	USD 407.73	USD 400.23
2025-12-19 (Friday)	35,564	USD 14,233,780	USD 14,233,780	-54	USD 127,627	USD 400.23	USD 396.04
2025-12-18 (Thursday)	35,618	USD 14,106,153	USD 14,106,153	-28	USD 129,356	USD 396.04	USD 392.1
2025-12-17 (Wednesday)	35,646	USD 13,976,797	USD 13,976,797	-162	USD -30,218	USD 392.1	USD 391.17
2025-12-16 (Tuesday)	35,808	USD 14,007,015	USD 14,007,015	-78	USD -42,354	USD 391.17	USD 391.5
2025-12-15 (Monday)	35,886	USD 14,049,369	USD 14,049,369	470	USD -30,262	USD 391.5	USD 397.55
2025-12-12 (Friday)	35,416	USD 14,079,631	USD 14,079,631	-54	USD -556,355	USD 397.55	USD 412.63
2025-12-11 (Thursday)	35,470	USD 14,635,986	USD 14,635,986	0	USD 289,790	USD 412.63	USD 404.46
2025-12-10 (Wednesday)	35,470	USD 14,346,196	USD 14,346,196	0	USD -381,303	USD 404.46	USD 415.21
2025-12-09 (Tuesday)	35,470	USD 14,727,499	USD 14,727,499	0	USD -525,310	USD 415.21	USD 430.02

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ALNY by Blackrock for IE00BYVJRR92

Show aggregate share trades of ALNY

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-23 BUY 135 407.425 396.020 397.160 USD 53,617 402.63
2025-12-22 SELL -162 413.490 403.200 404.229 USD -65,485 402.58 Loss of -266 on sale
2025-12-19 SELL -54 408.140 396.060 397.268 USD -21,452 402.61 Profit of 288 on sale
2025-12-18 SELL -28 404.190 391.510 392.778 USD -10,998 402.67 Profit of 277 on sale
2025-12-17 SELL -162 400.210 389.000 390.121 USD -63,200 402.76 Profit of 2,048 on sale
2025-12-16 SELL -78 399.570 388.540 389.643 USD -30,392 402.87 Profit of 1,032 on sale
2025-12-15 BUY 470 402.330 390.050 391.278 USD 183,901 402.98
2025-12-12 SELL -54 410.040 387.030 389.331 USD -21,024 403.03 Profit of 740 on sale
2025-12-08 SELL -405 449.780 423.450 426.083 USD -172,564 402.54 Loss of -9,537 on sale
2025-12-04 BUY 837 476.810 463.030 464.408 USD 388,709 401.35
2025-11-28 SELL -107 455.755 444.430 445.562 USD -47,675 398.87 Loss of -4,997 on sale
2025-11-25 SELL -297 441.820 428.570 429.895 USD -127,679 397.54 Loss of -9,610 on sale
2025-11-24 SELL -444 444.670 420.345 422.778 USD -187,713 397.14 Loss of -11,383 on sale
2025-11-20 SELL -54 467.730 445.340 447.579 USD -24,169 396.16 Loss of -2,776 on sale
2025-11-19 SELL -81 465.320 456.900 457.742 USD -37,077 395.44 Loss of -5,047 on sale
2025-11-18 SELL -135 469.110 456.270 457.554 USD -61,770 394.68 Loss of -8,488 on sale
2025-11-14 SELL -162 461.960 448.280 449.648 USD -72,843 393.28 Loss of -9,132 on sale
2025-11-12 SELL -810 459.270 447.130 448.344 USD -363,159 391.85 Loss of -45,762 on sale
2025-11-10 SELL -54 449.680 440.930 441.805 USD -23,857 390.51 Loss of -2,770 on sale
2025-11-07 SELL -27 443.587 430.835 432.110 USD -11,667 389.86 Loss of -1,141 on sale
2025-11-05 SELL -54 438.530 417.000 419.153 USD -22,634 388.66 Loss of -1,647 on sale
2025-10-29 SELL -189 481.590 482.730 482.616 USD -91,214 384.58 Loss of -18,528 on sale
2025-10-23 SELL -54 464.000 468.860 468.374 USD -25,292 379.67 Loss of -4,790 on sale
2025-10-21 SELL -54 474.000 490.050 488.445 USD -26,376 377.03 Loss of -6,016 on sale
2025-10-16 SELL -27 481.070 488.390 487.658 USD -13,167 372.07 Loss of -3,121 on sale
2025-10-14 SELL -108 469.360 479.690 478.657 USD -51,695 368.96 Loss of -11,847 on sale
2025-10-13 SELL -27 464.950 473.650 472.780 USD -12,765 367.42 Loss of -2,845 on sale
2025-09-26 SELL -54 446.400 453.050 452.385 USD -24,429 359.79 Loss of -5,000 on sale
2025-09-24 SELL -57 458.370 462.690 462.258 USD -26,349 356.37 Loss of -6,036 on sale
2025-09-18 SELL -54 452.170 456.940 456.463 USD -24,649 354.59 Loss of -5,501 on sale
2025-09-10 BUY 52 469.310 480.050 478.976 USD 24,907 341.05
2025-09-08 SELL -268 455.030 463.000 462.203 USD -123,870 335.50 Loss of -33,956 on sale
2025-08-06 SELL -216 428.140 428.690 428.635 USD -92,585 325.18 Loss of -22,347 on sale
2025-08-04 SELL -54 419.560 422.640 422.332 USD -22,806 320.48 Loss of -5,500 on sale
2025-07-31 SELL -667 392.240 402.430 401.411 USD -267,741 316.45 Loss of -56,671 on sale
2025-07-30 SELL -364 339.800 345.980 345.362 USD -125,712 315.82 Loss of -10,755 on sale
2025-07-29 SELL -196 330.550 331.060 331.009 USD -64,878 315.41 Loss of -3,058 on sale
2025-07-28 SELL -252 324.790 331.430 330.766 USD -83,353 315.14 Loss of -3,938 on sale
2025-07-18 BUY 27 320.530 325.620 325.111 USD 8,778 314.81
2025-07-17 BUY 818 324.690 329.870 329.352 USD 269,410 314.50
2025-07-16 SELL -216 322.810 323.410 323.350 USD -69,844 314.24 Loss of -1,969 on sale
2025-07-15 SELL -162 311.120 316.900 316.322 USD -51,244 314.34 Loss of -321 on sale
2025-07-11 BUY 108 314.940 321.120 320.502 USD 34,614 314.27
2025-07-10 BUY 162 322.640 324.820 324.602 USD 52,586 313.96
2025-07-09 SELL -135 320.870 322.680 322.499 USD -43,537 313.69 Loss of -1,189 on sale
2025-07-08 SELL -736 317.500 328.990 327.841 USD -241,291 313.54 Loss of -10,526 on sale
2025-06-27 SELL -351 322.830 323.200 323.163 USD -113,430 309.04 Loss of -4,956 on sale
2025-06-26 SELL -27 318.250 325.000 324.325 USD -8,757 308.53 Loss of -426 on sale
2025-06-24 SELL -73 325.000 326.030 325.927 USD -23,793 306.67 Loss of -1,406 on sale
2025-06-20 SELL -552 309.700 314.500 314.020 USD -173,339 305.99 Loss of -4,434 on sale
2025-06-17 SELL -1,160 308.710 309.060 309.025 USD -358,469 304.59 Loss of -5,146 on sale
2025-06-13 SELL -135 307.990 308.020 308.017 USD -41,582 303.75 Loss of -577 on sale
2025-06-12 BUY 130 304.670 307.480 307.199 USD 39,936 303.63
2025-06-09 SELL -297 304.000 306.170 305.953 USD -90,868 304.80 Loss of -342 on sale
2025-06-06 SELL -78 300.830 310.220 309.281 USD -24,124 305.79 Loss of -272 on sale
2025-06-04 SELL -513 305.310 308.930 308.568 USD -158,295 304.93 Loss of -1,866 on sale
2025-06-03 SELL -135 303.770 307.850 307.442 USD -41,505 306.09 Loss of -183 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-23	BUY	135	407.425	396.020	397.160	USD 53,617	402.63
2025-12-22	SELL	-162	413.490	403.200	404.229	USD -65,485	402.58 Loss of -266 on sale
2025-12-19	SELL	-54	408.140	396.060	397.268	USD -21,452	402.61 Profit of 288 on sale
2025-12-18	SELL	-28	404.190	391.510	392.778	USD -10,998	402.67 Profit of 277 on sale
2025-12-17	SELL	-162	400.210	389.000	390.121	USD -63,200	402.76 Profit of 2,048 on sale
2025-12-16	SELL	-78	399.570	388.540	389.643	USD -30,392	402.87 Profit of 1,032 on sale
2025-12-15	BUY	470	402.330	390.050	391.278	USD 183,901	402.98
2025-12-12	SELL	-54	410.040	387.030	389.331	USD -21,024	403.03 Profit of 740 on sale
2025-12-08	SELL	-405	449.780	423.450	426.083	USD -172,564	402.54 Loss of -9,537 on sale
2025-12-04	BUY	837	476.810	463.030	464.408	USD 388,709	401.35
2025-11-28	SELL	-107	455.755	444.430	445.562	USD -47,675	398.87 Loss of -4,997 on sale
2025-11-25	SELL	-297	441.820	428.570	429.895	USD -127,679	397.54 Loss of -9,610 on sale
2025-11-24	SELL	-444	444.670	420.345	422.778	USD -187,713	397.14 Loss of -11,383 on sale
2025-11-20	SELL	-54	467.730	445.340	447.579	USD -24,169	396.16 Loss of -2,776 on sale
2025-11-19	SELL	-81	465.320	456.900	457.742	USD -37,077	395.44 Loss of -5,047 on sale
2025-11-18	SELL	-135	469.110	456.270	457.554	USD -61,770	394.68 Loss of -8,488 on sale
2025-11-14	SELL	-162	461.960	448.280	449.648	USD -72,843	393.28 Loss of -9,132 on sale
2025-11-12	SELL	-810	459.270	447.130	448.344	USD -363,159	391.85 Loss of -45,762 on sale
2025-11-10	SELL	-54	449.680	440.930	441.805	USD -23,857	390.51 Loss of -2,770 on sale
2025-11-07	SELL	-27	443.587	430.835	432.110	USD -11,667	389.86 Loss of -1,141 on sale
2025-11-05	SELL	-54	438.530	417.000	419.153	USD -22,634	388.66 Loss of -1,647 on sale
2025-10-29	SELL	-189	481.590	482.730	482.616	USD -91,214	384.58 Loss of -18,528 on sale
2025-10-23	SELL	-54	464.000	468.860	468.374	USD -25,292	379.67 Loss of -4,790 on sale
2025-10-21	SELL	-54	474.000	490.050	488.445	USD -26,376	377.03 Loss of -6,016 on sale
2025-10-16	SELL	-27	481.070	488.390	487.658	USD -13,167	372.07 Loss of -3,121 on sale
2025-10-14	SELL	-108	469.360	479.690	478.657	USD -51,695	368.96 Loss of -11,847 on sale
2025-10-13	SELL	-27	464.950	473.650	472.780	USD -12,765	367.42 Loss of -2,845 on sale
2025-09-26	SELL	-54	446.400	453.050	452.385	USD -24,429	359.79 Loss of -5,000 on sale
2025-09-24	SELL	-57	458.370	462.690	462.258	USD -26,349	356.37 Loss of -6,036 on sale
2025-09-18	SELL	-54	452.170	456.940	456.463	USD -24,649	354.59 Loss of -5,501 on sale
2025-09-10	BUY	52	469.310	480.050	478.976	USD 24,907	341.05
2025-09-08	SELL	-268	455.030	463.000	462.203	USD -123,870	335.50 Loss of -33,956 on sale
2025-08-06	SELL	-216	428.140	428.690	428.635	USD -92,585	325.18 Loss of -22,347 on sale
2025-08-04	SELL	-54	419.560	422.640	422.332	USD -22,806	320.48 Loss of -5,500 on sale
2025-07-31	SELL	-667	392.240	402.430	401.411	USD -267,741	316.45 Loss of -56,671 on sale
2025-07-30	SELL	-364	339.800	345.980	345.362	USD -125,712	315.82 Loss of -10,755 on sale
2025-07-29	SELL	-196	330.550	331.060	331.009	USD -64,878	315.41 Loss of -3,058 on sale
2025-07-28	SELL	-252	324.790	331.430	330.766	USD -83,353	315.14 Loss of -3,938 on sale
2025-07-18	BUY	27	320.530	325.620	325.111	USD 8,778	314.81
2025-07-17	BUY	818	324.690	329.870	329.352	USD 269,410	314.50
2025-07-16	SELL	-216	322.810	323.410	323.350	USD -69,844	314.24 Loss of -1,969 on sale
2025-07-15	SELL	-162	311.120	316.900	316.322	USD -51,244	314.34 Loss of -321 on sale
2025-07-11	BUY	108	314.940	321.120	320.502	USD 34,614	314.27
2025-07-10	BUY	162	322.640	324.820	324.602	USD 52,586	313.96
2025-07-09	SELL	-135	320.870	322.680	322.499	USD -43,537	313.69 Loss of -1,189 on sale
2025-07-08	SELL	-736	317.500	328.990	327.841	USD -241,291	313.54 Loss of -10,526 on sale
2025-06-27	SELL	-351	322.830	323.200	323.163	USD -113,430	309.04 Loss of -4,956 on sale
2025-06-26	SELL	-27	318.250	325.000	324.325	USD -8,757	308.53 Loss of -426 on sale
2025-06-24	SELL	-73	325.000	326.030	325.927	USD -23,793	306.67 Loss of -1,406 on sale
2025-06-20	SELL	-552	309.700	314.500	314.020	USD -173,339	305.99 Loss of -4,434 on sale
2025-06-17	SELL	-1,160	308.710	309.060	309.025	USD -358,469	304.59 Loss of -5,146 on sale
2025-06-13	SELL	-135	307.990	308.020	308.017	USD -41,582	303.75 Loss of -577 on sale
2025-06-12	BUY	130	304.670	307.480	307.199	USD 39,936	303.63
2025-06-09	SELL	-297	304.000	306.170	305.953	USD -90,868	304.80 Loss of -342 on sale
2025-06-06	SELL	-78	300.830	310.220	309.281	USD -24,124	305.79 Loss of -272 on sale
2025-06-04	SELL	-513	305.310	308.930	308.568	USD -158,295	304.93 Loss of -1,866 on sale
2025-06-03	SELL	-135	303.770	307.850	307.442	USD -41,505	306.09 Loss of -183 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ALNY

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	216,727	3,259	396,243	54.7%
2025-09-18	172,875	397	386,432	44.7%
2025-09-17	246,547	167	472,292	52.2%
2025-09-16	88,846	60	226,336	39.3%
2025-09-15	148,258	13,572	435,689	34.0%
2025-09-12	134,122	300	244,968	54.8%
2025-09-11	219,868	7,820	411,702	53.4%
2025-09-10	543,326	7,595	916,898	59.3%
2025-09-09	705,540	33,731	1,550,899	45.5%
2025-09-08	175,158	440	388,715	45.1%
2025-09-05	127,116	335	311,252	40.8%
2025-09-04	110,930	2,555	236,568	46.9%
2025-09-03	182,386	8,982	562,921	32.4%
2025-09-02	132,770	14,416	358,476	37.0%
2025-08-29	93,216	2,181	276,594	33.7%
2025-08-28	60,182	1,254	226,865	26.5%
2025-08-27	277,667	1,084	440,577	63.0%
2025-08-26	243,404	919	447,421	54.4%
2025-08-25	156,551	15,662	374,276	41.8%
2025-08-22	228,596	1,309	408,152	56.0%
2025-08-21	123,996	2,862	248,300	49.9%
2025-08-20	149,638	13,723	316,983	47.2%
2025-08-19	144,320	1,143	308,399	46.8%
2025-08-18	371,318	34,264	525,786	70.6%
2025-08-15	104,018	13,245	265,620	39.2%
2025-08-14	133,272	4,443	505,528	26.4%
2025-08-13	183,271	1,390	1,017,623	18.0%
2025-08-12	173,045	4,046	693,018	25.0%
2025-08-11	239,199	7,600	451,248	53.0%
2025-08-08	168,755	3,199	466,744	36.2%
2025-08-07	308,810	4,452	527,399	58.6%
2025-08-06	202,151	12,590	548,349	36.9%
2025-08-05	256,295	13,237	826,283	31.0%
2025-08-04	411,114	36,303	729,949	56.3%
2025-08-01	350,060	60,108	764,943	45.8%
2025-07-31	829,191	6,023	1,541,015	53.8%
2025-07-30	533,885	14,703	942,788	56.6%
2025-07-29	164,268	55	384,537	42.7%
2025-07-28	150,240	69	571,965	26.3%
2025-07-25	90,782	429	298,801	30.4%
2025-07-24	132,001	11,546	286,155	46.1%
2025-07-23	184,149	63	312,340	59.0%
2025-07-22	134,761	7,553	524,612	25.7%
2025-07-21	113,303	101	243,119	46.6%
2025-07-18	84,117	9	196,317	42.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares MSCI USA SRI UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	SUUS(GBX) LSE
ETF Ticker	QDVR(EUR) F
ETF Ticker	QDVR.DE(EUR) CXE
ETF Ticker	SUAS.LS(USD) CXE
ETF Ticker	SUASz(USD) CXE
ETF Ticker	SUAU.AS(EUR) CXE
ETF Ticker	SUAS(EUR) ETF Plus
ETF Ticker	SUAU(EUR) Euronext Amsterdam
ETF Ticker	SUUS.L(GBP) LSE